Allostatine 1

Primary Application: Advanced Cancer Vaccine Support and Adjuvant Therapy

Fundamental Information

• Amino Acid Sequence: His-Gly-Val-Ser-Gly-Trp-Gly-Gln-His-Gly-Thr-His-Gly

• Classification: Humanized Alloferon Analog

• Target Motif: IgG CDR3 region mimicry

• Potency: Highly active at nanogram-per-milliliter concentrations

Detailed Overview

Allostatine 1 is a specialized version of Alloferon that was “humanized” to work more effectively within the human immune system. By changing just two amino acids in the original insect sequence, scientists designed the peptide to mimic an ancient and highly conserved pattern found in the CDR3 region of human antibodies. This structural tweak allows Allostatine to help the immune system recognize and attack malignant cells with much higher precision than its predecessor.

The most impressive data for Allostatine comes from its use as an “adjuvant”—a substance that makes vaccines work better. In leukemia research models, combining a tumor vaccine with Allostatine 1 led to a 95% total response rate, with 30% of the subjects achieving a complete cure from the disease. This significantly outperformed the results of the vaccine or Alloferon alone. Because it works at extremely small concentrations, it is considered a very precise tool for researching how to “train” the immune system to fight cancers that have become resistant to other treatments.

Scientific References

1. Chernysh S, Kozuharova I. “Anti-tumor activity of a peptide combining patterns of insect alloferons and mammalian immunoglobulins in naive and tumor antigen vaccinated mice.” Int Immunopharmacol. 2013;17(4):1090-3.

2. Scieuzo C, et al. “Modulation of immune responses using adjuvants to facilitate therapeutic vaccination.” ResearchGate. 2020.